03 Aug 2026
Biocon launched Yesafili commercially in the United States, an interchangeable biosimilar to Regeneron's Eylea 2 mg.
The launch follows a settlement with Regeneron that fixed the US entry window, on an approval the FDA granted in 2024. Interchangeable status is the commercial lever: a pharmacist can substitute it for Eylea without the prescriber intervening, which is how a biosimilar takes share quickly rather than converting physicians one patient at a time.